
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omilancor
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : NImmune Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
NImmune Acquires Omilancor Rights for Asian Market Expansion
Details : Through the acquisition, NImmune will gain global rights to BT-11 (omilancor) along with the portfolio of immunoregulators. BT-11 is currently being assessed for the treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Omilancor
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : NImmune Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, LianBio will assign to Janssen exclusive rights to develop and commercialize first-in-class radio enhancer NBTXR3 (hafnium oxide) in China, South Korea, Singapore, and Thailand for the treatment of locally advanced head and neck squa...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 26, 2023
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : $350.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, BMS has obtained LianBio’s exclusive rights for Camzyos (mavacamten), the first and only cardiac myosin inhibitor approved, in Mainland China and Asia for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : $350.0 million
Deal Type : Licensing Agreement

Details : BBP-398 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BBP-398,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mut...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2023
Lead Product(s) : BBP-398,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BBP-398,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung can...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : BBP-398,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LianBio Announces Marketing Approval of CAMZYOS (mavacamten) in Singapore
Details : Camzyos (mavacamten), a cardiac myosin inhibitor, recently got approved in Macau for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Tarsus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2023
Lead Product(s) : Lotilaner
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Tarsus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
